Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

23andMe

23andMe
2006 FOUNDED
PRIVATE STATUS
601-700 EMPLOYEES
2ndary - Private LATEST DEAL TYPE
45 INVESTORS
Description

Operator of a consumer genetics and research platform designed to help people access, understand and benefit from the human genome. The company's consumer genetics and research platform provides web-based interactive tools for individuals to learn and explore their own genetic information through DNA analysis technologies, enabling patients to gain deeper insights into personal ancestry, genealogy and inherited traits.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Laboratory Services (Healthcare)
Primary Office
  • 899 West Evelyn Avenue
  • Mountain View, CA 94041
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore 23andMe’s full profile, request a free trial.

23andMe Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
16. Secondary Transaction - Private 01-May-2019 00000 Completed Generating Revenue
15. Later Stage VC 31-Mar-2019 00000 Completed Generating Revenue
14. Later Stage VC 27-Dec-2018 00000 00000 00.00 Completed Generating Revenue
13. Secondary Transaction - Private 03-Dec-2018 00000 Completed Generating Revenue
12. Later Stage VC 01-Jan-2018 00000 Completed Generating Revenue
11. Secondary Transaction - Private 22-Dec-2017 00000 Completed Generating Revenue
10. Later Stage VC (Series F) 12-Sep-2017 00000 00000 00.000 Completed Generating Revenue
9. Later Stage VC 00.000 00000 Completed Generating Revenue
8. Grant 13-Oct-2016 $1.7M $241M Completed Generating Revenue
7. Grant 05-Apr-2016 $250K $241M Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

23andMe Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series F1 00,000,000 00.000000 00.00 000.00 000.00 00 000.00 000
Series F 00,000,000 00.000000 00.00 000.00 000.00 00 000.00 00.00
Series E 00,000,000 00.000000 00.00 000.00 000.00 00 000.00 0.000
Series D 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series C 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series B 9,048,560 $0.000010 $0.18 $3.07 $3.07 1x $3.07 6.28%
Series A 7,119,936 $0.000010 $0.08 $1.26 $1.26 1x $1.26 4.94%
To view this company’s complete Cap Table, request access »

23andMe Competitors (16)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sorenson Genomics Corporate Backed or Acquired Salt Lake City, UT 000000&0
0000000 00000000 Venture Capital-Backed San Diego, CA 000 00000 00000000000 00000
00000000000 000000 Venture Capital-Backed Palo Alto, CA 000 00000 0000000000 0 00000
00000 00000000 Private Equity-Backed Aliso Viejo, CA 000 00000 000000&0 00000
0000000 0000000000 Venture Capital-Backed Tokyo, Japan 0000 0000000000 0 0000
To view this company’s complete list of competitors, request access »

23andMe Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 13-Dec-2018 0000 00000 0000 Social/Platform Software
000000 00 000000 20-Jul-2015 00000 00000 00 0000 Other Healthcare Services 0000 00000000
CureTogether 10-Jul-2012 Merger/Acquisition Decision/Risk Analysis 0000 00000000
To view this company’s complete investment and acquisition history, request access »

23andMe Investors (45)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Next Ventures Venture Capital Minority 000 0000 000000 0
Hendale Capital Growth/Expansion Minority 000 0000 000000 0
Hercules Capital Lender/Debt Provider Minority 000 0000 000000 0
Quantum Global Partners Venture Capital Minority 000 0000 000000 0
GlaxoSmithKline Corporation Minority 000 0000 000000 0
You’re viewing 5 of 45 investors. Get the full list »

23andMe Executive Team (39)

Name Title Board
Seat
Contact
Info
Anne Wojcicki Co-Founder, Chief Executive Officer & Board Member
Steve Schoch Chief Financial Officer
Kathy Hibbs JD Chief Legal & Regulatory Officer
Michele Mieuli Director, Corporate & Business Development
Erik Karrer Ph.D Director of Target Discovery

25 Former Executives

You’re viewing 5 of 39 executives. Get the full list »

23andMe Board Members (7)

Name Representing Role Since Contact
Info
Anne Wojcicki 23andMe Co-Founder, Chief Executive Officer & Board Member 000 0000
Esther Dyson Self Board Member 000 0000
Neal Mohan 23andMe Board Member 000 0000
Roelof Botha Sequoia Capital Board Member 000 0000

3 Former Board Members

You’re viewing 4 of 7 board members. Get the full list »